Advanced Oncotherapy (AVO) – Exercise of Options and Issue of Shares

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that is has today issued 36,946 new ordinary shares of 25 pence in the Company to Dr Enrico Vanni, a non-executive director, at a subscription price of 101.5 pence per Ordinary Share (being the closing mid price on 04 November 2016) in lieu of his non-executive director fee for the fifteen months to September 2016.

Following this transaction, Dr Vanni now holds 598,946 Ordinary Shares representing 0.83% of the issued share capital of the Company.

The Company further announces that it has issued 266,668 new ordinary shares (“New Shares”) of 25 pence in the Company following the exercise of options issued in April 2014, at a subscription price of 87.5 pence per Ordinary Share.

Application has been made for the 303,614 New Shares to be admitted to trading on AIM and it is expected that Admission will occur on 11 November 2016.

Following Admission, the Company’s enlarged issued share capital will comprise 72,492,288 Ordinary Shares, with voting rights. The Company does not hold any Ordinary Shares in treasury. Therefore the total number of Ordinary Shares in the Company with voting rights will be 72,492,288. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules. 

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy’s team “ADAM”, based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.